Skip to main content
SpringerLink
Log in

Identify potentially inappropriate medications in older adults with chronic kidney disease and deprescribe when possible

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Older adults with chronic kidney disease (CKD) often receive treatment with multiple medications and are vulnerable to adverse treatment-related outcomes. Although specific guidelines for deprescribing (defined as the process of eliminating or reducing the use of unnecessary and/or inappropriate medications) in older patients with CKD are lacking, a systemic process should be used to assess the individual patient, identify the use of potentially inappropriate medications (PIMs), and deprescribe such medications when possible. Dosage tapering is needed when some commonly used PIMs (e.g. proton pump inhibitors and oral antidiabetic drugs) are deprescribed, but not when others (e.g. statins) are discontinued. Patient involvement and a collaborative approach are important factors in the success of the deprescribing process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Triantafylidis LK, Hawley CE, Perry LP, et al. The role of deprescribing in older adults with chronic kidney disease. Drugs Aging. 2018;35(11):973–84.

    Article  PubMed  Google Scholar 

  2. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.

    Article  PubMed  Google Scholar 

  3. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Blix HS, Viktil KK, Moger TA, et al. Use of renal risk drugs in hospitalized patients with impaired renal function: an underestimated problem? Nephrol Dial Transplant. 2006;21(11):3164–71.

    Article  PubMed  Google Scholar 

  5. Chang F, O’Hare AM, Miao Y, et al. Use of renally inappropriate medications in older veterans: a national study. J Am Geriatr Soc. 2015;63(11):2290–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgrad Med J. 2013;1051(89):247–50.

    Article  Google Scholar 

  7. American Geriatrics Society. Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.

    Article  Google Scholar 

  8. Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57(2):335–40.

    Article  PubMed  Google Scholar 

  9. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280.

    Article  CAS  PubMed  Google Scholar 

  10. Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011;9(5):423–30.

    Article  PubMed  PubMed Central  Google Scholar 

  11. McIntyre C, McQuillan R, Bell C, et al. Targeted deprescribing in an outpatient hemodialysis unit: a quality improvement study to decrease polypharmacy. Am J Kid Dis. 2017;70(5):611–8.

    Article  PubMed  Google Scholar 

  12. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–42.

    Article  CAS  PubMed  Google Scholar 

  13. Reeve E, Andrews JM, Wiese MD, et al. Feasibility of a patient-centered deprescribing pross to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49(1):28–38.

    Article  Google Scholar 

  14. Improving care and promoting health in populations. standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S7–12.

    Google Scholar 

  15. Moreno G, Mangione CM, Kimbro L, et al. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020–6.

    Article  PubMed  Google Scholar 

  16. Moreno G, Mangione CM. Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc. 2013;61(11):2027–37.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–56.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic agents in older persons: evidence-based clinical practice guideline. Can Fam Physician. 2017;63(11):832–43.

    PubMed  PubMed Central  Google Scholar 

  19. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016.

  20. American Diabetes Association. Position statement 9: pharmacological approaches to glycemia treatment: Standards of Medical Care in Diabetes—2019. Diabetes Car. 2019;42(Suppl 1):S90–102.

    Article  Google Scholar 

  21. American Diabetes Association. Position Statement 11: microvascular complications and foot care: Standards of Medical Care in Diabetes - 2019. Diabetes Car. 2019;42(Suppl 1):S124–38.

    Article  Google Scholar 

  22. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  CAS  PubMed  Google Scholar 

  23. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    Article  CAS  PubMed  Google Scholar 

  24. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and metaanalysis. Ann Intern Med. 2012;157(4):263–75.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829–39.

    Article  CAS  PubMed  Google Scholar 

  26. Kurella Tamura M, Covinsky KE, Chertow GM, et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med. 2009;361(16):1539–47.

    Article  PubMed  Google Scholar 

  27. Schlanger LE, Bailey JL, Sands JM. Geriatric nephrology: old or new subspecialty. Clin Geriatr Med. 2009;25(3):311–24.

    Article  PubMed  Google Scholar 

  28. Lee SJ, Kim CM. Individualizing prevention for older adults. J Am Geriatr Soc. 2018;66(2):229–34.

    Article  PubMed  Google Scholar 

  29. Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA. 2013;310(24):2609–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. De Vriese AS. Should statins be banned from dialysis? J Am Soc Nephrol. 2017;28(6):1675–6.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Holmes HM, Todd A. Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med. 2015;175(5):701–2.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM. 2017;110(8):493–500.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

    Adis Medical Writers

Authors
  1. Adis Medical Writers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adis Medical Writers.

Ethics declarations

Conflict of interest

The article was adapted from Drugs & Aging 2018;35(11):973–84 [1] by employees of Adis International Ltd/Springer Nature, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Writers, A.M. Identify potentially inappropriate medications in older adults with chronic kidney disease and deprescribe when possible. Drugs Ther Perspect 35, 376–380 (2019). https://doi.org/10.1007/s40267-019-00639-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-019-00639-3

Search

Navigation